
Biofrontera (BFRI) Stock Forecast & Price Target
Biofrontera (BFRI) Analyst Ratings
Bulls say
Biofrontera Inc is positioned for significant revenue growth due to the anticipated market launches of new indications for treating superficial Basal Cell Carcinoma and Actinic Keratoses, projected for 2026 and 2027. The company stands to benefit from an increase in sales personnel and favorable reimbursement policies, enhancing the competitive edge of its flagship product, Ameluz, over cryotherapy and attracting new customers to photodynamic therapy. Additionally, historical sales trends indicate that the fourth quarter, bolstered by increased dosage options for Ameluz, will likely be crucial for driving revenue growth this year.
Bears say
Biofrontera Inc. is facing a negative outlook primarily due to its revenue performance, which for the period amounted to $8.6 million, significantly below both the company's and consensus estimates of $10.6 million. This revenue shortfall raises concerns about the company's ability to execute on its growth strategy, as reflected in the downward adjustment of its price target from $7 to $2.75 per share based on comparative group averages. Additionally, potential regulatory surprises could further hinder revenue generation and escalate operational costs, compounding the challenges the company currently faces.
This aggregate rating is based on analysts' research of Biofrontera and is not a guaranteed prediction by Public.com or investment advice.
Biofrontera (BFRI) Analyst Forecast & Price Prediction
Start investing in Biofrontera (BFRI)
Order type
Buy in
Order amount
Est. shares
0 shares